3,010 Shares of United Therapeutics Corporation $UTHR Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, Holdings Channel.com reports. The institutional investor bought 3,010 shares of the biotechnology company’s stock, valued at approximately $1,631,000.

Several other hedge funds also recently bought and sold shares of UTHR. Toth Financial Advisory Corp increased its position in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $30,000. Caitlin John LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $37,000. International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares during the period. Finally, PFS Partners LLC acquired a new position in shares of United Therapeutics in the 3rd quarter worth approximately $45,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.7%

NASDAQ:UTHR opened at $562.02 on Friday. United Therapeutics Corporation has a 12-month low of $444.04 and a 12-month high of $614.23. The firm has a market cap of $23.94 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 3.59 and a beta of 0.49. The stock has a fifty day moving average price of $533.99 and a 200 day moving average price of $533.42.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $7.16 EPS. Equities analysts forecast that United Therapeutics Corporation will post 24.77 EPS for the current year.

United Therapeutics declared that its board has approved a stock repurchase program on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 411,028 shares of company stock valued at $218,476,169. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on UTHR shares. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a research report on Thursday. Raymond James Financial set a $720.00 target price on United Therapeutics in a research report on Wednesday. The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research report on Thursday, October 15th. BTIG Research upped their price target on United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised their price target on United Therapeutics from $700.00 to $703.00 and gave the stock an “overweight” rating in a research report on Thursday. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $676.40.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.